Published in Journal of Neurotrauma · View the paper (DOI)
Researchers developed a point-of-care GFAP assay that delivers results in minutes, outperforming the current FDA-cleared assay. The assay's diagnostic performance was significantly better than that of the S100B biomarker, validating its utility as a diagnostic marker for CT-detected lesions.
Coverage from 2 institutions